Omapatrilat—the story of Overture and Octave
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
At the American College of Cardiology in March two major trials were presented. The publicity surrounding the two could not have been more different. The LIFE demonstrated clear superiority of losartan-based therapy over atenolol-based therapy for the treatment of hypertension. It was published the same week in the Lancet and received major press coverage all over the world. The OVERTURE (Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events) study in contrast received a subdued reception, very little publicity and is yet to be published. 5770 NYHA class II-IV heart failure patients (LVEF<or=30%, recent heart failure hospital admission) were randomised and uptitrated to either 10 mg BD of Enalapril or 40 mg once a day Omapatrilat. The primary end-point of all cause mortality or heart failure related hospitalisation did not differ significantly: 914/2884 for Enalapril and 914/2886 for Omapatrilat (hazard ratio 0.94, CI's 0.86-1.03, P=0.187). Mortality was also similar: 509 for Enalapril and 477 for Omapatrilat (hazard ratio 0.94, CI's 0.83-1.07, P=0.339). Omapatrilat was as good as Enalapril but not better. The worrying trend was however, that angioedema was more common with Omapatrilat; 24 (0.8%) versus 14 cases (0.5%). The OCTAVE (Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril) study was also presented at this time. 25,267 hypertensives were randomised to Omapatrilat or enalapril and a difference of approximately 3 mmHg in favour of Om…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pharmacologic inhibition of both ACE and NEP increases the risk of angioedema when compared to ACE inhibition alone.[24]”
From Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema (2010) · cites this paper as [24]
In the citing paper
“This racial difference suggests that genetic factors modulate AE risk, but environmental factors are also important, because smokers taking ACEi have an increased susceptibility to AE (Coats 2002; Kostis et al. 2004).”
From A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. (2005) · cites this paper as Coats 2002
In the citing paper
“environmental factors are also important, because smokers taking ACEi have an increased susceptibility to AE (Coats 2002; Kostis et al. 2004).”
From A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. (2005) · cites this paper as Coats 2002
Citations
Cites
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08090-x · Cited by 1,560
Plasma bradykinin in angio-oedema
Nussberger, J., Cugno, M., Amstutz, C., Cicardi, M., Pellacani, A., & Agostoni, A. (1998) · The Lancet · doi:10.1016/s0140-6736(97)09137-x · Cited by 706
Rouleau, J. L., Pfeffer, M. A., Stewart, D. J., Isaac, D., Sestier, F., Kerut, E. K., Porter, C. B., Proulx, G., Qian, C., & Block, A. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02602-7 · Cited by 396
Angioedema due to angiotensin-converting enzyme inhibitors
Agostoni, A., Cicardi, M., Cugno, M., Zingale, L. C., Gioffré, D., & Nussberger, J. (1999) · Immunopharmacology · doi:10.1016/s0162-3109(99)00107-1 · Cited by 147
Heart failure 99 — the Moxcon story
Coats, A. J. S. (1999) · International Journal of Cardiology · doi:10.1016/s0167-5273(99)00120-5 · Cited by 83
Self-citationCampese, V. M., Lasseter, K. C., Ferrario, C. M., Smith, W. B., Ruddy, M. C., Grim, C. E., Smith, R. D., Vargas, R., Habashy, M. F., Vesterqvist, O., et al. (2001) · Hypertension · doi:10.1161/hy1201.096569 · Cited by 59
van Veldhuisen, D. J., & Poole-Wilson, P. A. (2001) · International Journal of Cardiology · doi:10.1016/s0167-5273(01)00447-8 · Cited by 51
Lapointe, N., Blais, C., Adam, A. A., Parker, T. G., Sirois, M. G., Gosselin, H., Clément, R., & Rouleau, J. L. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01837-5 · Cited by 48
Design of the omapatrilat in persons with enhanced risk of atherosclerotic events (OPERA) trial
Kostis, J. B., Cobbe, S. M., Johnston, C. I., Ford, I., Murphy, M. B., Weber, M. A., Black, H. R., Plouin, P., Levy, D. A., Mancia, G., et al. (2002) · American Journal of Hypertension · doi:10.1016/s0895-7061(01)02048-9 · Cited by 22
Research works printed but not linked: 1
- Angioedema due to ACE inhibitors: common and inadequately diagnosed. Prescrire Int 1998;7(35):92–93.
Cited by
Agostoni, A., Aygören-Pürsün, E., Binkley, K. E., Blanch, A., Bork, K., Bouillet, L., Bucher, C., Castaldo, A. J., Cicardi, M., Davis, A. E., et al. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.06.047 · Cited by 646
“Following the example put forth in the large-scale trial of antihypertensive agents that showed (1) African descent and, to a lesser extent, (2) smoking to correlate with increased angioedema risk, 250 clinicians and researchers may wish to investigate the interaction of these variables with C1-INH deficiency.”
InfluentialAce revisited: A new target for structure-based drug design
Acharya, K. R., Sturrock, E. D., Riordan, J. F., & Ehlers, M. R. W. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1227 · Cited by 342
“The clinical results with omapatrilat have had a sobering effect on the field 88 and have indicated that broad inhibition of vasoregulatory peptides should be approached with caution 89 .”
BackgroundArendse, L. B., Danser, A. H. J., Poglitsch, M., Touyz, R. M., Burnett, J. C., Llorens-Cortes, C., Ehlers, M. R., & Sturrock, E. D. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017129 · Cited by 339
“To further study the efficacy and safety of omapatrilat, large randomized clinical trials were undertaken to assess the efficacy and safety profile of omapatrilat in patients with hypertension and heart failure, compared with the conventional ACE inhibitor enalapril (Coats, 2002) .”
Targeting Metalloenzymes for Therapeutic Intervention
Chen, A. Y., Adamek, R. N., Dick, B. L., Credille, C. V., Morrison, C. N., & Cohen, S. M. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00201 · Cited by 270
KURTZ, S. M., OCHOA, J. A., LAU, E., SHKOLNIKOV, Y., PAVRI, B. B., FRISCH, D., & GREENSPON, A. J. (2010) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.2009.02670.x · Cited by 217
Metadata
- Authors
- Coats, A. J. S.
- Affiliations
- Royal Brompton Hospital (GB)
- Corresponding author
- Coats, Andrew J.S
- ORCID
- Coats, Andrew J.S
- Venue
- International Journal of Cardiology
- Publisher
- Elsevier BV
- Published
- 2002-11
- Volume
- 86
- Issue
- 1
- Pages
- 1-4
- ISSN
- 0167-5273 (ISSN-L)
- OpenAlex
- W2168106055
- Cited by
- 107
- References
- 17
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2022: 1 · 2021: 6 · 2020: 2 · 2019: 3 · 2018: 1 · 2017: 5 · 2016: 2 · 2015: 2 · 2013: 2 · 2012: 3
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- International Journal of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- omapatrilat, heart failure, ACE inhibitors, enalapril, losartan, atenolol, hypertension, drug trials, media coverage
- MeSH terms
- Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Clinical Trials as Topic, Drug Industry, Enalapril, Heart Failure, Humans, Pyridines, Research Support as Topic, Thiazepines, Treatment Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Omapatrilat—the story of Overture and Octave. https://app.cochat.ai/papers/10.1016/s0167-5273(02)00389-3
- The paper
- Coats, A. J. S. (2002). Omapatrilat—the story of Overture and Octave. International Journal of Cardiology. https://doi.org/10.1016/s0167-5273(02)00389-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.